Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 82

1.

Treatment outcomes after initiation of exenatide twice daily or insulin in clinical practice: 12-month results from CHOICE in six European countries.

Ostenson CG, Matthaei S, Reaney M, Krarup T, Guerci B, Kiljanski J, Salaun-Martin C, Sapin H, Bruhn D, Mathieu C, Theodorakis M.

Diabetes Metab Syndr Obes. 2013 Apr 26;6:171-85. doi: 10.2147/DMSO.S41827. Print 2013.

2.

Using Exenatide Twice Daily or Insulin in Clinical Practice: Results from CHOICE.

Mathieu C, Ostenson CG, Matthaei S, Reaney M, Krarup T, Guerci B, Kiljański J, Salaun-Martin C, Sapin H, Theodorakis M.

Diabetes Ther. 2013 Dec;4(2):285-308. doi: 10.1007/s13300-013-0037-8. Epub 2013 Sep 10.

3.

Resource use and costs of exenatide bid or insulin in clinical practice: the European CHOICE study.

Kiiskinen U, Matthaei S, Reaney M, Mathieu C, Ostenson CG, Krarup T, Theodorakis M, Kiljański J, Salaun-Martin C, Sapin H, Guerci B.

Clinicoecon Outcomes Res. 2013 Jul 11;5:355-67. doi: 10.2147/CEOR.S44060. Print 2013.

4.

Patient-reported outcomes among patients using exenatide twice daily or insulin in clinical practice in six European countries: the CHOICE prospective observational study.

Reaney M, Mathieu C, Ostenson CG, Matthaei S, Krarup T, Kiljański J, Salaun-Martin C, Sapin H, Theodorakis M, Guerci B.

Health Qual Life Outcomes. 2013 Dec 26;11:217. doi: 10.1186/1477-7525-11-217.

5.

Patients with Type 2 Diabetes Initiating Exenatide Twice Daily or Insulin in Clinical Practice: CHOICE Study.

Matthaei S, Reaney M, Mathieu C, Ostenson CG, Krarup T, Guerci B, Kiljanski J, Petto H, Bruhn D, Theodorakis M.

Diabetes Ther. 2012 Nov;3(1):6. doi: 10.1007/s13300-012-0006-7. Epub 2012 Jun 20.

7.

Combination therapy with insulin glargine and exenatide: real-world outcomes in patients with type 2 diabetes.

Levin P, Wei W, Wang L, Pan C, Douglas D, Baser O.

Curr Med Res Opin. 2012 Mar;28(3):439-46. doi: 10.1185/03007995.2012.654850. Epub 2012 Jan 23.

PMID:
22216894
8.

Exenatide BID and liraglutide QD treatment patterns among type 2 diabetes patients in Germany.

Miller LA, Burudpakdee C, Zagar A, Bhosle M, Reaney M, Schabert VF, Bruhn D.

J Med Econ. 2012;15(4):746-57. doi: 10.3111/13696998.2012.679756. Epub 2012 Apr 3.

PMID:
22443463
9.

Newer agents for blood glucose control in type 2 diabetes: systematic review and economic evaluation.

Waugh N, Cummins E, Royle P, Clar C, Marien M, Richter B, Philip S.

Health Technol Assess. 2010 Jul;14(36):1-248. doi: 10.3310/hta14360. Review.

10.

Exenatide versus insulin glargine in patients with suboptimally controlled type 2 diabetes: a randomized trial.

Heine RJ, Van Gaal LF, Johns D, Mihm MJ, Widel MH, Brodows RG; GWAA Study Group.

Ann Intern Med. 2005 Oct 18;143(8):559-69.

PMID:
16230722
11.

Persistence with injectable antidiabetic agents in members with type 2 diabetes in a commercial managed care organization.

Cooke CE, Lee HY, Tong YP, Haines ST.

Curr Med Res Opin. 2010 Jan;26(1):231-8. doi: 10.1185/03007990903421994.

PMID:
19921965
13.

Clinical outcomes of concomitant therapy of exenatide twice daily and basal insulin in patients with type 2 diabetes mellitus: a retrospective database analysis in the United States.

Pawaskar M, Li Q, Hoogwerf BJ, Reynolds MW, Lee LJ, Fonseca V.

Endocr Pract. 2012 Sep-Oct;18(5):700-11. doi: 10.4158/EP11367.OR.

PMID:
22982784
14.

Effects of exenatide versus insulin analogues on weight change in subjects with type 2 diabetes: a pooled post-hoc analysis.

Glass LC, Qu Y, Lenox S, Kim D, Gates JR, Brodows R, Trautmann M, Bergenstal RM.

Curr Med Res Opin. 2008 Mar;24(3):639-44. doi: 10.1185/030079908X260862. Epub 2008 Jan 23.

PMID:
18218179
15.

Exenatide: an incretin mimetic for the treatment of type 2 diabetes mellitus.

Iltz JL, Baker DE, Setter SM, Keith Campbell R.

Clin Ther. 2006 May;28(5):652-65. Review.

PMID:
16861088
16.

Comparison of biphasic insulin aspart 30 given three times daily or twice daily in combination with metformin versus oral antidiabetic drugs alone in patients with poorly controlled type 2 diabetes: a 16-week, randomized, open-label, parallel-group trial conducted in russia.

Ushakova O, Sokolovskaya V, Morozova A, Valeeva F, Zanozina O, Sazonova O, Zhadanova E, Starceva M, Kazakova E, Saifullina M, Shapiro I, Tarasov A, Al-Tayar B, Starkova N.

Clin Ther. 2007 Nov;29(11):2374-84.

PMID:
18158078
17.

Clinical outcomes using long-term combination therapy with insulin glargine and exenatide in patients with type 2 diabetes mellitus.

Levin PA, Mersey JH, Zhou S, Bromberger LA.

Endocr Pract. 2012 Jan-Feb;18(1):17-25. doi: 10.4158/EP11097.OR.

PMID:
21742605
18.

Metabolic outcomes of matched patient populations initiating exenatide BID vs. insulin glargine in an ambulatory care setting.

Pawaskar M, Li Q, Hoogwerf BJ, Reynolds MW, Faries D, Engelman W, Bruhn D, Bergenstal RM.

Diabetes Obes Metab. 2012 Jul;14(7):626-33. doi: 10.1111/j.1463-1326.2012.01581.x. Epub 2012 Mar 8.

PMID:
22321776
19.

Exenatide effects on diabetes, obesity, cardiovascular risk factors and hepatic biomarkers in patients with type 2 diabetes treated for at least 3 years.

Klonoff DC, Buse JB, Nielsen LL, Guan X, Bowlus CL, Holcombe JH, Wintle ME, Maggs DG.

Curr Med Res Opin. 2008 Jan;24(1):275-86.

PMID:
18053320
20.

Metabolic outcomes of elderly patient populations initiating exenatide BID versus insulin glargine in an ambulatory care setting.

Pawaskar M, Li Q, Reynolds MW.

Curr Med Res Opin. 2012 Jun;28(6):991-7. doi: 10.1185/03007995.2012.686901. Epub 2012 May 9.

PMID:
22519390
Items per page

Supplemental Content

Write to the Help Desk